Our Services
Medical Information
Helpful Resources
Published on: 9/17/2026
Most clinicians recommend giving Lexapro (escitalopram) at least 4 to 6 weeks at an adequate dose before deciding it isn't working, since early side effects often fade by week 2 and full antidepressant benefit can take 6 to 8 weeks. If you notice no improvement at all by week 4, a dose increase is usually tried first, while partial improvement often warrants waiting the full 8 weeks before switching. Switching too soon is one of the most common reasons people cycle through multiple antidepressants without relief, though worsening mood, new suicidal thoughts, or intolerable side effects are reasons to contact your prescriber right away rather than waiting. Timing also depends on your dose, how long you've been at it, and whether a cross-taper or washout period is needed, so there are several important factors to consider before making a change. See below to understand more.
If you're unsure whether what you're feeling is a sign your medication needs more time, a dose adjustment, or a different approach entirely, it helps to get a structured read on your symptoms before your next appointment. A free, instant, online symptom check asks the same kinds of questions a clinician would, then helps you organize your experience into clear information you can bring to your prescriber. That means less guessing, better questions, and a faster path to the treatment that actually works for you.
Last reviewed for medical accuracy: 09/17/2026
Deciding when to switch from Lexapro (escitalopram) to another antidepressant can feel overwhelming, especially if you’re asking, “why am i still depressed even on lexapro?” Below is a clear, step-by-step guide based on credible clinical guidelines and expert consensus.
Key point: Don’t judge Lexapro too early. Early side effects (nausea, headache, fatigue) often improve before mood lifts do.
Regular check-ins with your prescriber help track real change:
Keep a simple mood diary or checklist of symptoms. Share it with your doctor.
If you’ve given Lexapro at least 6–8 weeks at a moderate dose and you’re seeing:
…then continuing makes sense. Often, a slow build in benefit continues beyond week 8.
Consider a switch if, after 8–12 weeks at an optimal dose, you have:
If you’re still stuck after these steps, a switch to another SSRI (e.g., sertraline, fluoxetine) or a different class (e.g., SNRI like venlafaxine) may be warranted.
If you’re unsure about your symptoms or next steps, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you organize your concerns and decide what to discuss at your next appointment.
free, online symptom check, using the doctor approved Ubie Symptom Checker
If you experience any of these, seek medical attention immediately—call your local emergency services or go to the nearest emergency department.
(References)
* Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, Barbui C, Leucht S, Furukawa TA. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. J Affect Disord. 2015 Jul 15;180:179-84. doi: 10.1016/j.jad.2015.03.021. Epub 2015 Mar 31. PMID: 25911132.
* Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, Coghill D, Zhang Y, Hazell P, Leucht S, Cuijpers P, Pu J, Cohen D, Ravindran AV, Liu Y, Michael KD, Yang L, Liu L, Xie P. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 2016 Aug 27;388(10047):881-90. doi: 10.1016/S0140-6736(16)30385-3. Epub 2016 Jun 8. PMID: 27289172.
* Yoon H, Oh DJ, Suh HS, Lee KU, Lim SW, Lee JY, Yang JC, Lee JH, Ha J, Lee BH, Kang SG, Yoon HK, Moon J, Bae SM, Kwon Y, Kim HC, Oh KS. Korean Guidelines for the Pharmacological Treatment of Social Anxiety Disorder: Initial Treatment Strategies. Psychiatry Investig. 2018 Feb;15(2):147-155. doi: 10.30773/pi.2017.05.01. Epub 2017 Nov 29. PMID: 29475215; PMCID: PMC5900408.
* Bahar MA, Lanting P, Bos JHJ, Sijmons RH, Hak E, Wilffert B. Impact of Drug-Gene-Interaction, Drug-Drug-Interaction, and Drug-Drug-Gene-Interaction on (es)Citalopram Therapy: The PharmLines Initiative. J Pers Med. 2020 Nov 28;10(4). doi: 10.3390/jpm10040256. Epub 2020 Nov 28. PMID: 33260705; PMCID: PMC7720126.
* Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, Cox GR, Merry SN, Meader N. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev. 2021 May 24;5(5):CD013674. doi: 10.1002/14651858.CD013674.pub2. Epub 2021 May 24. PMID: 34029378; PMCID: PMC8143444.
* Yatham LN, Arumugham SS, Kesavan M, Ramachandran K, Murthy NS, Saraf G, Ouyang Y, Bond DJ, Schaffer A, Ravindran A, Ravindran N, Frey BN, Daigneault A, Beaulieu S, Lam RW, Kondapuram N, Reddy MS, Bhandary RP, Ashok MV, Ha K, Ahn YM, Milev R, Wong H, Reddy YCJ, BEAM-BD Trial Group. Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. N Engl J Med. 2023 Aug 3;389(5):430-440. doi: 10.1056/NEJMoa2300184. PMID: 37530824.
* Salian HH, Raghav MV, Rawat VS, Divakar A. Cost-minimization analysis of escitalopram, fluoxetine, and amitriptyline in the treatment of depression. Indian J Pharmacol. 2023 Sep-Oct;55(5):293-298. doi: 10.4103/ijp.ijp_854_22. PMID: 37929407; PMCID: PMC10751525.
* Kessing LV, Ziersen SC, Andersen FM, Gerds T, Budtz-Jørgensen E. Comparative responses to 17 different antidepressants in major depressive disorder: Results from a 2-year long-term nation-wide population-based study emulating a randomized trial. Acta Psychiatr Scand. 2024 May;149(5):378-388. doi: 10.1111/acps.13673. Epub 2024 Feb 20. PMID: 38379028.
* Chen A, Metzger E, Lee S, Osser D. A Proposed Algorithm for the Pharmacological Treatment of Generalized Anxiety Disorder in the Older Patient. J Geriatr Psychiatry Neurol. 2025 May;38(3):155-171. doi: 10.1177/08919887241289533. Epub 2024 Oct 1. PMID: 39352792.
* Chatterjee SS, Mukherjee S, Das S, Kayal M, Mondal S. Quetiapine Extended-Release and Peripheral Edema: A Case Report and Literature Review. Case Rep Psychiatry. 2025;2025:5806365. doi: 10.1155/crps/5806365. Epub 2025 Oct 31. PMID: 41211119; PMCID: PMC12595240.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.